<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765023</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_ATM_101</org_study_id>
    <nct_id>NCT01765023</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Fixed-sequence Study to Evaluate Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the pharmacokinetic interactions between atorvastatin&#xD;
      and metformin single or co-administered in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate PK interaction of atorvastatin and metformin</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate PK interaction of 2-OH-atorvastatin and metformin</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : atorvastatin, Period II : atorvastatin and metformin</intervention_name>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : metformin, Period II : atorvastatin and metformin</intervention_name>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to adhere to protocol requirements and sign a informed consent form&#xD;
&#xD;
          2. Healthy male volunteers who are in age range of 20-55 years and the weight range is&#xD;
             not exceed Â±20% of ideal weight. Ideal weight = [height -100]*0.9&#xD;
&#xD;
          3. Subjects with no history of any significant chronic disease&#xD;
&#xD;
          4. Judged to be in good health on the basis of their vital sign, ECG, physical exam and&#xD;
             routine laboratory data for this trial by investigators&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects taking inducer or inhibitor of drug metabolism enzyme such as barbital within&#xD;
             28days prior to study medication dosing&#xD;
&#xD;
          2. Subjects with Symptoms of acute disease within 28days prior to study medication dosing&#xD;
&#xD;
          3. Subjects with a history of gastrointestinal diseases which might significantly change&#xD;
             ADME of medicines&#xD;
&#xD;
          4. Subjects with a history of abdominal surgery within food and water limit&#xD;
&#xD;
          5. Subjects with a history of clinically significant allergies including drug allergies&#xD;
&#xD;
          6. Subjects with anaphylaxis to atorvastatin and/or metformin&#xD;
&#xD;
          7. Subjects with a history or plan iodine radiotherapy within 28 days prior to drug&#xD;
             administration&#xD;
&#xD;
          8. Subjects with a history of myopathy&#xD;
&#xD;
          9. Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
&#xD;
         10. Clinical laboratory test values are outside the accepted normal range&#xD;
&#xD;
               -  AST or ALT &gt;1.25 times to normal range&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 times to normal range&#xD;
&#xD;
               -  Creatinine clearance &lt;90 mL/min&#xD;
&#xD;
         11. Subjects with a history of drug, caffeine and alcohol abuse(caffeine &gt; 5cups/day,&#xD;
             cigarette &gt; 10/day, alcohol &gt; 30g/day) or have ever drank within 7 days prior to drug&#xD;
             administration&#xD;
&#xD;
         12. Special diet known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior&#xD;
             to drug administration&#xD;
&#xD;
         13. Donated blood within 60 days prior to dosing&#xD;
&#xD;
         14. Participated in a previous clinical trial within 60 days prior to dosing&#xD;
&#xD;
         15. Subjects who have received any drugs that might confound the results of the trial&#xD;
             based on medical judgement by investigators within 10days prior to drug administration&#xD;
&#xD;
         16. Subjects considered as unsuitable based on medical judgement by investigators&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>April 7, 2013</last_update_submitted>
  <last_update_submitted_qc>April 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

